HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M,
HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M, Q2 Operating Income $7.158M